Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CN5Q | ISIN: US91864C1071 | Ticker-Symbol: 2AB
Frankfurt
27.06.25 | 08:02
0,755 Euro
+3,42 % +0,025
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,7550,81027.06.

Aktuelle News zur BARINTHUS BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BARINTHUS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
10.06.Barinthus Biotherapeutics plc. - 8-K, Current Report1
09.06.Barinthus Biotherapeutics plc: Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025128OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June...
► Artikel lesen
07.05.Barinthus Biotherapeutics plc. - 10-Q, Quarterly Report4
07.05.Barinthus Biotherapeutics plc. - 8-K, Current Report1
20.03.Barinthus Biotherapeutics plc. - S-8, Securities to be offered to employees in employee benefit plans2
20.03.Barinthus Biotherapeutics plc. - 10-K, Annual Report2
20.03.Barinthus Biotherapeutics Plc Full Year Loss Narrows-
20.03.Barinthus Biotherapeutics plc. - 8-K, Current Report2
20.03.Barinthus Biotherapeutics: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments846Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000)...
► Artikel lesen
06.03.Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11248NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About...
► Artikel lesen
10.01.Barinthus Bio's UK COO, CFO To Leave, Plans To Cut 65% Headcount To Expand Cash Runway-
10.01.Barinthus Bio shifts focus, cuts workforce to extend cash runway1
10.01.Barinthus Biotherapeutics: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update414Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending...
► Artikel lesen
10.01.Barinthus Biotherapeutics plc. - 8-K, Current Report-
15.11.24Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B400Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom...
► Artikel lesen
15.11.24Barinthus Biotherapeutics: Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion190Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United...
► Artikel lesen
06.11.24Barinthus Biotherapeutics: Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results169OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that...
► Artikel lesen
01.10.24Barinthus Biotherapeutics: Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer134Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update for HBV003 anticipated in Q4 2024.Data update...
► Artikel lesen
24.09.24Barinthus Biotherapeutics: Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease349Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1